Qiagen NV - Asset Resilience Ratio
Qiagen NV (QGEN) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Qiagen NV (QGEN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2025)
This chart shows how Qiagen NV's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Qiagen NV to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Qiagen NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qiagen NV market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Qiagen NV maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Qiagen NV Industry Peers by Asset Resilience Ratio
Compare Qiagen NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Qiagen NV (1996–2025)
The table below shows the annual Asset Resilience Ratio data for Qiagen NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.13% | $259.91 Million | $6.30 Billion | -4.47pp |
| 2024-12-31 | 8.60% | $489.44 Million | $5.69 Billion | +2.23pp |
| 2023-12-31 | 6.37% | $389.70 Million | $6.12 Billion | -4.56pp |
| 2022-12-31 | 10.94% | $687.60 Million | $6.29 Billion | +7.93pp |
| 2021-12-31 | 3.01% | $184.78 Million | $6.15 Billion | +1.01pp |
| 2020-12-31 | 2.00% | $117.25 Million | $5.87 Billion | -0.48pp |
| 2019-12-31 | 2.48% | $129.59 Million | $5.24 Billion | -1.61pp |
| 2018-12-31 | 4.08% | $234.61 Million | $5.75 Billion | -3.05pp |
| 2017-12-31 | 7.13% | $359.20 Million | $5.04 Billion | +4.97pp |
| 2016-12-31 | 2.16% | $93.00 Million | $4.31 Billion | -0.96pp |
| 2015-12-31 | 3.12% | $130.82 Million | $4.19 Billion | -1.01pp |
| 2014-12-31 | 4.13% | $184.04 Million | $4.45 Billion | +2.91pp |
| 2013-12-31 | 1.22% | $49.92 Million | $4.09 Billion | -0.97pp |
| 2012-12-31 | 2.19% | $90.45 Million | $4.13 Billion | +0.74pp |
| 2011-12-31 | 1.45% | $54.58 Million | $3.76 Billion | -1.26pp |
| 2010-12-31 | 2.71% | $106.08 Million | $3.91 Billion | +1.66pp |
| 2009-12-31 | 1.05% | $40.00 Million | $3.80 Billion | +0.97pp |
| 2007-12-31 | 0.08% | $2.31 Million | $2.78 Billion | -4.27pp |
| 2006-12-31 | 4.35% | $52.78 Million | $1.21 Billion | +2.39pp |
| 2005-12-31 | 1.96% | $15.00 Million | $765.30 Million | -2.26pp |
| 2004-12-31 | 4.22% | $30.15 Million | $714.60 Million | +3.04pp |
| 2003-12-31 | 1.18% | $6.53 Million | $551.93 Million | -1.35pp |
| 2002-12-31 | 2.54% | $11.53 Million | $454.51 Million | -3.77pp |
| 2001-12-31 | 6.31% | $22.51 Million | $356.97 Million | -9.88pp |
| 2000-12-31 | 16.19% | $37.27 Million | $230.26 Million | -5.43pp |
| 1999-12-31 | 21.62% | $32.02 Million | $148.12 Million | -0.69pp |
| 1998-12-31 | 22.31% | $23.80 Million | $106.70 Million | -10.39pp |
| 1997-12-31 | 32.70% | $25.80 Million | $78.90 Million | -9.75pp |
| 1996-12-31 | 42.45% | $28.10 Million | $66.20 Million | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more